273 related articles for article (PubMed ID: 9892598)
1. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism.
Reed GL; Houng AK
Circulation; 1999 Jan; 99(2):299-304. PubMed ID: 9892598
[TBL] [Abstract][Full Text] [Related]
2. Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation.
Singh S; Houng A; Reed GL
Circulation; 2017 Mar; 135(11):1011-1020. PubMed ID: 28028005
[TBL] [Abstract][Full Text] [Related]
3. Alpha 2-antiplasmin causes thrombi to resist fibrinolysis induced by tissue plasminogen activator in experimental pulmonary embolism.
Butte AN; Houng AK; Jang IK; Reed GL
Circulation; 1997 Apr; 95(7):1886-91. PubMed ID: 9107177
[TBL] [Abstract][Full Text] [Related]
4. Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII.
Rijken DC; Abdul S; Malfliet JJ; Leebeek FW; Uitte de Willige S
J Thromb Haemost; 2016 Jul; 14(7):1453-61. PubMed ID: 27148673
[TBL] [Abstract][Full Text] [Related]
5. Post-thrombolysis haemostasis changes after rt-PA treatment in acute cerebral infarct. Correlations with cardioembolic aetiology and outcome.
Sun X; Berthiller J; Derex L; Trouillas P; Diallo L; Hanss M
J Neurol Sci; 2015 Feb; 349(1-2):77-83. PubMed ID: 25619569
[TBL] [Abstract][Full Text] [Related]
6. Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes.
Agren A; Jörneskog G; Elgue G; Henriksson P; Wallen H; Wiman B
Diabetes Care; 2014 Jul; 37(7):2007-14. PubMed ID: 24760258
[TBL] [Abstract][Full Text] [Related]
7. Evidence that alpha2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis regulation.
Mosesson MW; Siebenlist KR; Hernandez I; Lee KN; Christiansen VJ; McKee PA
J Thromb Haemost; 2008 Sep; 6(9):1565-70. PubMed ID: 18564219
[TBL] [Abstract][Full Text] [Related]
8. Antibody-directed fibrinolysis. An antibody specific for both fibrin and tissue plasminogen activator.
Bode C; Runge MS; Branscomb EE; Newell JB; Matsueda GR; Haber E
J Biol Chem; 1989 Jan; 264(2):944-8. PubMed ID: 2492021
[TBL] [Abstract][Full Text] [Related]
9. Thrombomodulin-dependent effect of factor V Leiden mutation on the cross-linking of α2-plasmin inhibitor to fibrin and its consequences on fibrinolysis.
Koncz Z; Bagoly Z; Haramura G; Mezei ZA; Muszbek L
Thromb Res; 2012 Sep; 130(3):528-34. PubMed ID: 22704462
[TBL] [Abstract][Full Text] [Related]
10. Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.
Mimuro J; Kimura S; Aoki N
J Clin Invest; 1986 Mar; 77(3):1006-13. PubMed ID: 2419360
[TBL] [Abstract][Full Text] [Related]
11. The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and alpha2-antiplasmin dependent.
Nielsen VG
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):584-7. PubMed ID: 20683324
[TBL] [Abstract][Full Text] [Related]
12. Influence of factor XIIIa activity on human whole blood clot lysis in vitro.
Jansen JW; Haverkate F; Koopman J; Nieuwenhuis HK; Kluft C; Boschman TA
Thromb Haemost; 1987 Apr; 57(2):171-5. PubMed ID: 2440124
[TBL] [Abstract][Full Text] [Related]
13. Plasma fibrin clots of pulmonary embolism patients present increased amounts of factor XIII and alpha2-antiplasmin at 3 months' anticoagulation since the acute phase.
Zabczyk M; Natorska J; Bagoly Z; Sarkady F; Barath B; Katona E; Bryk A; Zettl K; Wisniewski JR; Undas A
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33214340
[TBL] [Abstract][Full Text] [Related]
14. A novel method to quantify fibrin-fibrin and fibrin-α
Morrow GB; Flannery S; Charles PD; Heilig R; Feller T; McQuilten Z; Wake E; Ariens RAS; Winearls J; Mutch NJ; Fischer R; Laffan MA; Curry N
J Thromb Haemost; 2024 Jun; 22(6):1758-1771. PubMed ID: 38462220
[TBL] [Abstract][Full Text] [Related]
15. Fibrin-fibrin and alpha 2-antiplasmin-fibrin cross-linking by platelet factor XIII increases the resistance of platelet clots to fibrinolysis.
Reed GL; Matsueda GR; Haber E
Trans Assoc Am Physicians; 1991; 104():21-8. PubMed ID: 1845147
[No Abstract] [Full Text] [Related]
16. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
[TBL] [Abstract][Full Text] [Related]
17. Effect of a synthetic carboxy-terminal peptide of alpha(2)-antiplasmin on urokinase-induced fibrinolysis.
Lee KN; Jackson KW; McKee PA
Thromb Res; 2002 Feb; 105(3):263-70. PubMed ID: 11927133
[TBL] [Abstract][Full Text] [Related]
18. Catalytic life of activated factor XIII in thrombi. Implications for fibrinolytic resistance and thrombus aging.
Robinson BR; Houng AK; Reed GL
Circulation; 2000 Sep; 102(10):1151-7. PubMed ID: 10973845
[TBL] [Abstract][Full Text] [Related]
19. Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.
Sakata Y; Aoki N
J Clin Invest; 1982 Mar; 69(3):536-42. PubMed ID: 7199538
[TBL] [Abstract][Full Text] [Related]
20. Enhanced lysis and accelerated establishment of viscoelastic properties of fibrin clots are associated with pulmonary embolism.
Martinez MR; Cuker A; Mills AM; Crichlow A; Lightfoot RT; Chernysh IN; Nagaswami C; Weisel JW; Ischiropoulos H
Am J Physiol Lung Cell Mol Physiol; 2014 Mar; 306(5):L397-404. PubMed ID: 24414255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
